CMTM6, a potential immunotherapy target
- 16 November 2021
- journal article
- review article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 148 (1) , 47-56
Abstract
The CKLF-like MARVEL transmembrane domain-containing protein 6 (CMTM6), which binds to the programmed death ligand 1 (PD-L1) and stabilizes the expression of PD-L1 on the cell surface, has been recently discovered as a novel regulator of PD-L1 expression in cancer. PD-L1 is an immune checkpoint inhibitory molecule that can mediate the immune escape of tumor cells in various tumors and has been studied intensively in recent years. In 2017, two articles simultaneously reported that CMTM6 can stabilize the expression of PD-L1 on the plasma membrane and prevent PD-L1 from being degraded by lysosomes; therefore, CMTM6 may play an important role in tumor cell immune escape and immunosuppression. At present, there are few studies on the relationship between the expression of CMTM6 and PD-L1 in different tumors and diseases. These studies together suggested that CMTM6 may be a potential novel immunotherapy target. In this review, we briefly describe the latest research progresses of CMTM6 in various cancers and other diseases.Keywords
This publication has 61 references indexed in Scilit:
- Identification of CMTM6 and CMTM4 as PD-L1 protein regulatorsNature, 2017
- CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunityNature, 2017
- Combination cancer immunotherapy and new immunomodulatory targetsNature Reviews Drug Discovery, 2015
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Global DNA methylation screening of liver in piperonyl butoxide-treated mice in a two-stage hepatocarcinogenesis modelToxicology Letters, 2013
- A novel 3p22.3 gene CMTM7 represses oncogenic EGFR signaling and inhibits cancer cell growthOncogene, 2013
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Prognostic impact of CD168 expression in gastric cancerBMC Cancer, 2011
- CMTM3, Located at the Critical Tumor Suppressor Locus 16q22.1, Is Silenced by CpG Methylation in Carcinomas and Inhibits Tumor Cell Growth through Inducing ApoptosisCancer Research, 2009
- CMTM5 Exhibits Tumor Suppressor Activities and Is Frequently Silenced by Methylation in Carcinoma Cell LinesClinical Cancer Research, 2007